Kyntra Bio: Nasdaq Staff determines to delist common stock

What happened Kyntra Bio reported that on Sep 30, 2026 it received a determination letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC notifying the Company that it had not demonstrated compliance with Nasdaq Listing Rule 5450(b) as of Sep 29, 2026 and that the Staff had determined to delist the Company’s common stock from the Nasdaq Global Select Market. The Company has timely requested a hearing before a Nasdaq Hearings Panel and asked for additional time to regain compliance.

Key details

• The Staff previously notified the Company on Apr 2, 2026 that it was not in compliance with Nasdaq Listing Rule 5450(b)(3)(A), which requires total assets and total revenue of at least $50,000,000 each for the most recently completed fiscal year or two of the three most recently completed fiscal years.
• The Company also did not satisfy the alternative stockholders’ equity or market value of listed securities standards under Nasdaq Listing Rule 5450(b).
• The Company requested a hearing, which stays the suspension of the Company’s securities and the filing of a Form 25-NSE while the Nasdaq Hearings Panel considers the matter.
• The Company noted an extension period could be up to 180 days from the Staff delisting determination pursuant to Listing Rule 5815(c)(1)(A). The Company’s common stock will remain listed and continue to trade on Nasdaq under the symbol KYNB pending the Panel’s decision.

Why it may matter This report was filed under Item 3.01, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard, which covers notices from an exchange or its staff about delisting or noncompliance with continued listing standards. A filing does not show why the insider traded or why the company acted.